Kairos Pharma, Ltd. (KAPA) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $1.82 (+0.55%), Market cap $0.01B, 52-week low–high $0.45 ~ $1.97.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS
Financial statements, price targets, institutional (13F) holdings and related news for Kairos Pharma, Ltd. are updated in real time on BlackAll Trade.
Kairos Pharma, Ltd. trades at $1.82 (+0.55%). Real-time quotes and charts are available on BlackAll Trade.
Kairos Pharma, Ltd. has a market cap of about $0.01B.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small